Rapid Titration With Intravenous Oxycodone for Severe Cancer Pain and Oral Conversion Ratio.


Journal

Journal of pain and symptom management
ISSN: 1873-6513
Titre abrégé: J Pain Symptom Manage
Pays: United States
ID NLM: 8605836

Informations de publication

Date de publication:
12 2022
Historique:
received: 17 06 2022
revised: 05 09 2022
accepted: 08 09 2022
pubmed: 18 9 2022
medline: 16 11 2022
entrez: 17 9 2022
Statut: ppublish

Résumé

to assess a dose titration with intravenous oxycodone to achieve rapid pain relief of cancer pain of severe intensity. The second objective was to provide a conversion ratio with the oral route. Cancer patients admitted for severe pain were prospectively assessed. At admission (T0) previous opioid doses were recorded. Edmonton symptom assessment scale (ESAS) was collected from T0 until the conclusion of the observation. Intravenous boluses of oxycodone were given until the initial signs of significant analgesia were detected. The effective dose was multiplied for six and given as intravenous continuous infusion. When the patient was considered stabilized the intravenous daily dose was converted to oral oxycodone using an initial ratio of 1:2. Subsequently, doses of oral oxycodone were changed according to the clinical situation. Twenty-nine patients were examined. A mean effective bolus dose of oxycodone was 9.5 mg (SD 8.0) allowed to achieve a meaningful pain relief in a mean of 10.4 minutes (SD 3.3). The mean initial and the final infusion doses were 51.0 mg/day (standard deviation 40.9) and 69.7 mg/day ( standard deviation76.6), respectively. A significant change in pain intensity was observed at the different time intervals (P<0.0005). Conversion to oral route occurred after a mean of 2.7 days (standard deviation1.2) of intravenous oxycodone. The final mean conversion ratio was 1:2,12 ( standard deviation0.36). Rapid intravenous oxycodone dose titration resulted in rapid pain relief. The intravenous-oral conversion ratio of 1:2 is reliable. Further studies are necessary to confirm this preliminary observation.

Identifiants

pubmed: 36115502
pii: S0885-3924(22)00897-1
doi: 10.1016/j.jpainsymman.2022.09.004
pii:
doi:

Substances chimiques

Oxycodone CD35PMG570
Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

532-536

Informations de copyright

Copyright © 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interest Statement None declared

Auteurs

Sebastiano Mercadante (S)

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy. Electronic address: terapiadeldolore@lamaddalenanet.it.

Claudio Adile (C)

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy.

Patrizia Ferrera (P)

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy.

Alessio Lo Cascio (AL)

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy.

Alessandra Casuccio (A)

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH